文献速递神经肿瘤

基于MRI影像组学特征的下级别胶质瘤1p/19q共缺失无创基因型预测:开发与验证

Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas.
PubMed 文献 · J Neurooncol · 2018-08-10

这项回顾性研究纳入277例组织病理学诊断为下级别胶质瘤的患者,提取647个MRI特征并用随机森林构建影像组学特征预测1p/19q共缺失,在训练队列(n=184)和独立验证队列(n=93)中评估。影像组学特征在训练和验证队列的AUC分别为0.887和0.760,优于临床模型(AUC 0.580和0.627),联合模型AUC为0.885和0.753,提示临床因素未带来额外改善。

要点

  • 影像组学特征在训练队列AUC为0.887,验证队列AUC为0.760。
  • 临床模型训练队列AUC为0.580,验证队列AUC为0.627。
  • 联合模型训练队列AUC为0.885,验证队列AUC为0.753,临床因素未带来额外改善。

核心结论

  • 基于MRI的影像组学特征能有效识别组织病理学诊断的下级别胶质瘤中的1p/19q共缺失,有望促进胶质瘤的无创分子亚型预测。

研究设计与样本

  • 回顾性研究纳入277例组织病理学诊断为下级别胶质瘤的患者,训练队列n=184,时间独立验证队列n=93。
  • 提取647个MRI特征,应用随机森林算法生成预测1p/19q共缺失的影像组学特征。
  • 临床模型由相关临床因素构成,使用逻辑回归算法构建;联合模型整合影像组学特征与相关临床因素。
  • 使用受试者工作特征曲线评估预测性能,并用时间独立验证队列验证三种模型的可预测性。

主要发现

  • 影像组学特征作为独立预测因子区分1p/19q共缺失基因型,训练队列AUC为0.887,验证队列AUC为0.760。
  • 临床模型训练队列AUC为0.580,验证队列AUC为0.627,影像组学特征表现优于临床模型。
  • 联合模型训练队列AUC为0.885,验证队列AUC为0.753,提示临床因素未带来额外改善。

关键数值与推荐

  • 影像组学特征训练队列AUC为0.887,验证队列AUC为0.760。
  • 临床模型训练队列AUC为0.580,验证队列AUC为0.627。
  • 联合模型训练队列AUC为0.885,验证队列AUC为0.753。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To perform radiomics analysis for non-invasively predicting chromosome 1p/19q co-deletion in World Health Organization grade II and III (lower-grade) gliomas. METHODS: This retrospective study included 277 patients histopathologically diagnosed with lower-grade glioma. Clinical parameters were recorded for each patient. We performed a radiomics analysis by extracting 647 MRI-based features and applied the random forest algorithm to generate a radiomics signature for predicting 1p/19q co-deletion in the training cohort (n = 184). The clinical model consisted of pertinent clinical factors, and was built using a logistic regression algorithm. A combined model, incorporating both the radiomics signature and related clinical factors, was also constructed. The receiver operating characteristics curve was used to evaluate the predictive performance. We further validated the predictability of the three developed models using a time-independent validation cohort (n = 93). RESULTS: The radiomics signature was constructed as an independent predictor for differentiating 1p/19q co-deletion genotypes, which demonstrated superior performance on both the training and validation cohorts with areas under curve (AUCs) of 0.887 and 0.760, respectively. These results outperformed the clinical model (AUCs of 0.580 and 0.627 on training and validation cohorts). The AUCs of the combined model were 0.885 and 0.753 on training and validation cohorts, respectively, which indicated that clinical factors did not present additional improvement for the prediction. CONCLUSION: Our study highlighted that an MRI-based radiomics signature can effectively identify the 1p/19q co-deletion in histopathologically diagnosed lower-grade gliomas, thereby offering the potential to facilitate non-invasive molecular subtype prediction of gliomas.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Han Y, Xie Z, Zang Y, et al. Non-invasive genotype prediction of chromosome 1p/19q co-deletion by development and validation of an MRI-based radiomics signature in lower-grade gliomas. J Neurooncol. 2018. PMID: 30097822. doi:10.1007/s11060-018-2953-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。